IP Library Granted Patent US 7,932,364
Granted Patent B2
US 7,932,364 · App. 10/556,094 · Granted Apr 26, 2011

Compositions and methods for the preparation of human growth hormone glycosylation mutants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,932,364
App. No.
10/556,094
Granted
Apr 26, 2011
Kind
B2
Abstract

The present invention relates to mutants of human growth hormone, which contain newly introduced N-linked or O-linked glycosylation site(s), such that these recombinantly produced polypeptides have glycosylation patterns distinctly different from that of the naturally occurring human growth hormone. The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compositions comprising the mutants and method for using the mutants.

Claims (35)

1. An isolated human growth hormone polypeptide comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 except for the presence of at least one O-linked glycosylation site not present in SEQ ID NO: 1 or SEQ ID NO: 2, wherein the O-linked glycosylation site is a serine or threonine residue, and wherein the O-linked glycosylation site is present at a site selected from the group consisting of (a) proximate a proline residue located at position 2, 5, 37, 48, 59, 89, or 133 of SEQ ID NO: 1 or SEQ ID NO: 2, (b) the amino acid sequence surrounding position 140 of SEQ ID NO: 1 or SEQ ID NO: 2, and (c) the amino acid sequence at the C-terminus of SEQ ID NO: 1 or SEQ ID NO: 2.

2. The isolated human growth hormone polypeptide of claim 1 , wherein the O-linked glycosylation site is present at a site proximate a proline residue located at position 2, 5, 37, 48, 59, 89, or 133 of SEQ ID NO: 1 or SEQ ID NO: 2.

3. The isolated human growth hormone polypeptide of claim 1 , comprising the amino acid sequence of SEQ ID NO: 3, 4, 5, 6, 7, 8, or 9.

4. The isolated human growth hormone polypeptide of claim 1 , comprising a plurality of O-linked glycosylation sites not present SEQ ID NO: 1 or SEQ ID NO: 2.

5. The isolated human growth hormone polypeptide of claim 1 , comprising a water-soluble polymer attached to the glycosylation site through a glycosyl linker.

6. The isolated human growth hormone polypeptide of claim 5 , wherein said glycosyl linker is an intact glycosyl linker.

7. A composition comprising the isolated human growth hormone polypeptide of claim 1 and a carrier therefor.

8. A method of making a glycosylated human growth hormone polypeptide comprising:

a) recombinantly producing the human growth hormone polypeptide of claim 1 ; and

b) glycosylating said human growth hormone polypeptide at the O-linked glycosylation site.

9. The method of claim 8 , wherein step b) comprises enzymatically glycosylating said human growth hormone polypeptide with a modified sugar at the O-linked glycosylation site.

10. The method of claim 9 , wherein the sugar is modified with a poly(ethylene glycol) or m-poly(ethylene glycol).

11. The method of claim 9 , wherein the O-linked glycosylation site is present at a site proximate a proline residue located at position 2, 5, 37, 48, 59, 89, or 133 of SEQ ID NO: 1 or SEQ ID NO: 2.

12. The method of claim 9 , wherein said human growth hormone polypeptide comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6, 7, 8, or 9.

13. The method of claim 9 , wherein said human growth hormone polypeptide comprises a plurality of O-linked glycosylation sites not present in SEQ ID NO: 1 or SEQ ID NO: 2.

14. The method of claim 9 , wherein said human growth hormone polypeptide comprises a water-soluble polymer attached to the glycosylation site through a glycosyl linker.

15. The method of claim 14 , wherein said glycosyl linker is an intact glycosyl linker.

16. The method of claim 8 , wherein the O-linked glycosylation site is present at a site proximate a proline residue located at position 2, 5, 37, 48, 59, 89, or 133 of SEQ ID NO: 1 or SEQ ID NO: 2.

17. The method of claim 8 , wherein said human growth hormone polypeptide comprises the amino acid sequence of SEQ ID NO: 3, 4, 5, 6, 7, 8, or 9.

18. The method of claim 8 , wherein said human growth hormone polypeptide comprises a plurality of O-linked glycosylation sites not present SEQ ID NO: 1 or SEQ ID NO: 2.

19. The method of claim 8 , wherein said human growth hormone polypeptide comprises a water-soluble polymer attached to the glycosylation site through a glycosyl linker.

20. The method of claim 19 , wherein said glycosyl linker is an intact glycosyl linker.

21. The isolated human growth hormone polypeptide of claim 1 , wherein the isolated human growth hormone polypeptide is glycosylated.

22. The isolated human growth hormone polypeptide of claim 2 , wherein the isolated human growth hormone polypeptide is glycosylated.

23. The isolated human growth hormone polypeptide of claim 3 , wherein the isolated human growth hormone polypeptide is glycosylated.

24. The isolated human growth hormone polypeptide of claim 4 , wherein the isolated human growth hormone polypeptide is glycosylated.

25. A composition comprising the isolated human growth hormone polypeptide of claim 2 and a carrier therefor.

26. A composition comprising the isolated human growth hormone polypeptide of claim 3 and a carrier therefor.

27. A composition comprising the isolated human growth hormone polypeptide of claim 4 and a carrier therefor.

28. A composition comprising the isolated human growth hormone polypeptide of claim 5 and a carrier therefor.

29. A composition comprising the isolated human growth hormone polypeptide of claim 6 and a carrier therefor.

30. A composition comprising the isolated human growth hormone polypeptide of claim 21 and a carrier therefor.

31. A composition comprising the isolated human growth hormone polypeptide of claim 22 and a carrier therefor.

32. A composition comprising the isolated human growth hormone polypeptide of claim 23 and a carrier therefor.

33. A composition comprising the isolated human growth hormone polypeptide of claim 24 and a carrier therefor.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE PLEASE CHANGE THE ASSIGNEE FROM BIOGENERIX AG TO NOVO NORDISK A/S. PREVIOUSLY RECORDED ON REEL 022404 FRAME 0634. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ASSIGNEE IS NOVO NORDISK A/S, NOVO ALLE, 2880 BAGSVAERD, DENMARK. Recorded Apr 9, 2009
From: BIOGENERIX AG
To: NOVO NORDISK A/S
Reel/Frame 022527/0614 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2009
From: NEOSE TECHNOLOGIES, INC.
To: NOVO NORDISK A/S
Reel/Frame 022441/0937 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2007
From: DEFREES, SHAWN; CLAUSEN, HENRIK
To: NEOSE TECHNOLOGIES, INC.
Reel/Frame 019293/0727 →